CCK receptor polymorphisms: an illustration of emerging themes in pharmacogenomics.

[1]  J. Crawley,et al.  International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. , 1999, Pharmacological reviews.

[2]  M. Relling,et al.  Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.

[3]  D. A. Mason,et al.  A Gain-of-function Polymorphism in a G-protein Coupling Domain of the Human β1-Adrenergic Receptor* , 1999, The Journal of Biological Chemistry.

[4]  A. Kopin,et al.  Interspecies Polymorphisms Confer Constitutive Activity to theMastomys Cholecystokinin-B/Gastrin Receptor* , 1998, The Journal of Biological Chemistry.

[5]  J A Tischfield,et al.  Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[6]  A. Kopin,et al.  Minor Modifications of a Cholecystokinin-B/Gastrin Receptor Non-peptide Antagonist Confer a Broad Spectrum of Functional Properties* , 1998, Journal of Biological Chemistry.

[7]  R. Erickson,et al.  Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. , 1997, The Journal of clinical investigation.

[8]  S. Liggett.  Polymorphisms of the β2-Adrenergic Receptor and Asthma , 1997 .

[9]  A. Kopin,et al.  Inter- and intraspecies polymorphisms in the cholecystokinin-B/gastrin receptor alter drug efficacy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[10]  H. Jüppner,et al.  A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. , 1995, Science.

[11]  J. Parma,et al.  Brief report: congenital hyperthyroidism caused by a mutation in the thyrotropin-receptor gene. , 1995, The New England journal of medicine.

[12]  Jacqueline N. Crawley,et al.  Biological actions of cholecystokinin , 1994, Peptides.

[13]  A. Nishida,et al.  Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo. , 1994, The Journal of pharmacology and experimental therapeutics.

[14]  J. Kemp,et al.  High-affinity and potent, water-soluble 5-amino-1,4-benzodiazepine CCKB/gastrin receptor antagonists containing a cationic solubilizing group. , 1994, Journal of medicinal chemistry.

[15]  S. Green,et al.  A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. , 1993, The Journal of biological chemistry.

[16]  T. Minegishi,et al.  A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty , 1993, Nature.

[17]  J. Parma,et al.  Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas , 1993, Nature.

[18]  L. F. Kolakowski,et al.  The human brain cholecystokinin-B/gastrin receptor. Cloning and characterization. , 1993, The Journal of biological chemistry.

[19]  A. Kopin,et al.  A single amino acid of the cholecystokinin-B/gastrin receptor determines specificity for non-peptide antagonists , 1993, Nature.

[20]  J. Lowe,et al.  Molecular basis for the species selectivity of the substance P antagonist CP-96,345. , 1993, The Journal of biological chemistry.

[21]  C. Strader,et al.  Molecular basis for the species selectivity of the neurokinin-1 receptor antagonists CP-96,345 and RP67580. , 1992, The Journal of biological chemistry.

[22]  B. O'dowd,et al.  A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors , 1992, Nature.

[23]  L. F. Kolakowski,et al.  Expression cloning and characterization of the canine parietal cell gastrin receptor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[24]  D. Horwell.  Development of CCK-B antagonists , 1991, Neuropeptides.

[25]  R. Chang,et al.  A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365,260. , 1989, European journal of pharmacology.